

Tobramycin is an aminoglycoside antibiotic used to treat eye infections, CF lung infections, and serious bacterial infections. Learn uses, dosage, and costs.
Tobramycin is an aminoglycoside antibiotic used to treat serious bacterial infections, including eye infections, Pseudomonas aeruginosa lung infections in cystic fibrosis patients, and systemic Gram-negative infections.
It's available under several brand names — Tobrex (eye drops), TOBI and TOBI Podhaler (inhaled forms), Bethkis, and Kitabis Pak — as well as in generic form. Tobramycin has been used since the 1970s and remains an important tool in fighting bacteria that are resistant to other antibiotics.
This guide covers everything you need to know about Tobramycin in 2026: what it treats, how it's taken, who should avoid it, and what it costs.
Tobramycin is FDA-approved for several conditions, depending on the formulation:
Tobramycin eye drops (0.3%) and ointment are used to treat bacterial conjunctivitis (pink eye), blepharitis, and other external eye infections caused by susceptible bacteria. They're one of the most commonly prescribed antibiotic eye drops and are approved for patients 2 months and older.
Inhaled Tobramycin — available as a nebulizer solution (300 mg/5 mL) or dry powder inhaler (TOBI Podhaler) — is used to manage chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients aged 6 and older. It's given in alternating 28-day on/off cycles to reduce lung bacterial load and improve breathing.
IV or IM Tobramycin is used for severe infections including:
It's particularly effective against Gram-negative bacteria like Pseudomonas aeruginosa, E. coli, Klebsiella, and Enterobacter species.
Doctors sometimes prescribe Tobramycin for conditions not on the official label, including empiric treatment of febrile neutropenia (in combination with beta-lactam antibiotics), peritonitis in peritoneal dialysis patients, and non-CF bronchiectasis with Pseudomonas colonization.
The dosage and method depend on which form you're using:
Tobramycin is not appropriate for everyone. You should not use it if you have:
Use with extreme caution if you have:
Always tell your doctor about all medications you're taking. Tobramycin has significant drug interactions that can increase the risk of kidney damage and hearing loss.
The price of Tobramycin varies enormously depending on the formulation:
For inhaled forms, insurance coverage and copay assistance are essential. Novartis offers the PODCARE+ Savings Card for TOBI Podhaler with up to $14,000 per year in copay assistance. Patient assistance programs are also available for uninsured or underinsured patients through the Novartis Patient Assistance Foundation.
For more ways to reduce your costs, see our guide on how to save money on Tobramycin.
Generic Tobramycin eye drops are covered by most plans with low copays (Tier 1–2). Injectable Tobramycin is typically covered under your medical benefit when given in a clinical setting. Inhaled Tobramycin often requires prior authorization and may need documentation of a CF diagnosis with Pseudomonas culture results.
Several alternatives to Tobramycin exist, depending on the use case:
Tobramycin is a versatile and effective antibiotic that has been a cornerstone of treatment for serious bacterial infections for decades. Whether you need it for a simple eye infection or as part of your cystic fibrosis care regimen, understanding how it works, how to take it, and what to watch for helps you get the most from your treatment.
If you're having trouble finding Tobramycin in stock or want to check pharmacy availability, Medfinder can help you locate it and compare prices near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.